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CC BY-NC-ND license (http://creativAbstract Background/Introduction: Previous studies have investigated the neuroprotective
effects of tamoxifen (TMX), but its antidepressant-like effects in traumatic brain injury
(TBI) remain unclear.
Purposes/Aims: The present study was conducted to determine whether TMX can attenuate
TBI-induced depression-like behavior and whether this effect involves the activation of extra-
cellular signal-regulated kinase 1/2 (ERK1/2).
Methods: Anesthetized male SpragueeDawley rats were divided into four groups: sham-
operated controls, TBI controls, TBI þ TMX treatment (1 mg/kg), and TMX (1 mg/
kg) þ ERK1/2 antagonist, SL327 (30 mg/kg). Depression-like behaviors were evaluated through
forced swim tests on Day 4, Day 8, and Day 15. On Day 15 after TBI, phosphorylated ERK1/2 (p-
ERK1/2) expression was investigated by Western blotting; neuronal apoptosis, p-ERK1/2, B-cell
chronic lymphocytic leukemia/lymphoma 2 (BCL2), and brain-derived neurotrophic factor
(BDNF ) expression in neuronal cells were evaluated using double immunofluorescence.
Results: On Day 15 after TBI, TMX significantly reduced the duration of TBI-induced immobility
compared with the TBI controls. The frequency of neuronal apoptosis and numbers of BCL2-
positive, BDNF-positive, and p-ERK1/2-positive neuronal cells in hippocampal CA3 were signif-
icantly improved by TMX. However, these TMX effects were significantly blocked by SL327
administration.
Conclusion: Our results suggest that intraperitoneal injection of TMX may ameliorate TBI-
induced depression-like behavior in rats by increasing neuronal p-ERK1/2 expression, which
may be associated with neuronal Bcl2 and BDNF expression and decreased neuronal apoptosis.port no biomedical financial interest or potential conflict of interest.
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Depression following a traumatic brain injury (TBI) is a se-
vere complication. The incidence of posttraumatic
depression is estimated to range from 10% to 77%, with
variation according to the studied population, diagnostic
criteria, and rating instruments used.1 This post-TBI
neuropsychiatric impairment contributes to disability
after TBI and has become a chronic condition in an esti-
mated 3.17 million Americans.2 Therefore, developing
novel therapeutic strategies and identifying new effective
therapies are crucial.
The hippocampus is a crucial component of the limbic
system, which is a site of the central nervous system that is
involved in depressive behavior.3 Previous studies have re-
ported that hippocampal CA3 neurons appear to be
particularly vulnerable to TBI,4,5 which increases the like-
lihood that an insult to the hippocampus CA3 can induce
hippocampal cell apoptosis and lead to depressive
behavior.
The extracellular signal-regulated kinase (ERK1/2)
pathways are associated with cell survival and apoptosis6
and ERK1/2-mediated neuroprotective effects such as
those induced through BCL2 and BDNF.7,8 A previous study
reported that the ERK1/2 signal transduction pathway in
the hippocampus, but not that in the amygdala, may be
involved in TBI-induced depression-like behavior in rats.9
Intraperitoneal tamoxifen (TMX), a selective estrogen re-
ceptor modulator (SERM), may ameliorate TBI in rats by
increasing neuronal ERK1/2 phosphorylation, which might
lead to an increase in neuronal Bcl2 expression and
decrease in neuronal apoptosis after cortical ischemia.10
Furthermore, Walf and Frye11 demonstrated that subcu-
taneous or direct administration of estrogen into the hip-
pocampus elicited antidepressant-like behavior compared
with vehicle administration. TMX treatment in cultured
hippocampal neurons increased the expression of the
antiapoptotic protein, BCL2, an outcome linked to the
neuroprotective effect of estrogen.12 These phenomena
increase the likelihood that TMX may have beneficial ef-
fects on TBI-induced apoptosis in hippocampal cells and
subsequent antidepressant effects.
The neuroprotective effects of estrogen in TBI have
been evaluated.13 However, applying estrogen as a neuro-
protective agent in humans may have several limitations
such as causing estrogen-dependent peripheral tumors. In
the current study, we selected TMX because, being a
nonsteroidal SERM, its estrogen-like neuroprotective ac-
tivity in the brain can act as an alternative agonist to es-
trogen14; it is braineblood barrier permeable, achieving an
increased concentration in the brain and serum upon
administration15; and most importantly, the directmechanism of TMX in TBI-induced depression-like behavior
remains unclear.
The forced swim test (FST) is one of the most common
animal models for assessing depression-like behavior.
Longer periods of immobility during the test indicate more
severe depression-like behaviors. Several antidepressants
have been consistently shown to reduce the duration of
immobility during testing by increasing active escape
behaviors.16,17
In the current study, we hypothesized that TMX would
have therapeutic effects on TBI-induced depression-like
behaviors and that its beneficial effects may be associated
with ERK1/2 expression. To test this hypothesis, we applied
SL327,18 a brain-penetrating selective inhibitor of ERK1/2
that selectively inhibits phosphorylated ERK1/2 (p-ERK1/2),
in the brain following systematic administration.19 We
investigated whether TMX in the presence or absence of
SL327 activates neuronal ERK1/2, BCL2, and BDNF re-
sponses; reduces neuronal cell apoptosis; and ameliorates
depression-like behaviors (evaluated by FST) after TBI in
adult rats.
2. Methods
2.1. Animals
Adult male SpragueeDawley rats weighing 397  23 g were
used in this study. The animals were maintained under a 12-
hour light/12-hour dark cycle and allowed free access to
both food and water. Before the study was initiated, all
protocols for the study followed the Animal Protection Act,
Council of Agriculture, Executive Yuan, Taiwan and were
approved by the Chi-Mei Medical Center’s Animal Care and
Use Committee (IACUC; Tainan, Taiwan) for all experi-
mental procedures (IACUC Approval No: 100120711). The
protocols also conformed to the National Institutes of
Health guidelines (Publication No. 85-23, revised 1985)
including minimizing discomfort to animals during surgery
and the recovery period.
2.2. TBI
The rats were anesthetized by intraperitoneal administra-
tion of a mixture of ketamine [44 mg/kg, intramuscularly
(i.m.); Nankuang Pharmaceutical, Tainan, Taiwan], atro-
pine (0.062633 mg/kg, i.m.; Sintong Chemical Ind. Co.,
Taoyuan, Taiwan), and xylazine (6.77 mg/kg, i.m.; Bayer,
Leverkusen, Germany). A craniectomy (radius Z 2 mm)
4 mm from the bregma and 3 mm from sagittal sutures in
the right parietal cortex was performed using a stereotaxic
frame. After craniectomy and implantation of an injury
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Biomedical Engineering, Richmond, VA, USA) was con-
nected to the rats through a Luer-lock fitting, and the brain
was injured through percussion (2.0e2.2 atm, 25 millisec-
onds). The details are described in our previous study.10
Transient hypertensive response, apnea, and seizure were
observed immediately following the FPI, and these symp-
toms were used as the criteria for dividing the animals into
the TBI and TBI þ treatment groups.
2.3. Treatment intervention
The experimental design was established in three parts
(Figure 1). In the first part of the study, the effects of TMX
on TBI-induced immobility were investigated on Day 4, Day
8, and Day 15 after TBI by FST. The effects of TMX on Erk1/2
expression in the hippocampus of the ipsilateral injury side
were investigated on Day 15 after TBI by Western blotting.
Moreover, whether SL327 would block the neuroprotective
effect of TMX in the CA3 region of the hippocampus ipsi-
lateral to the injury side was assessed by immunofluores-
cence staining. The effects of SL327 on depression-like
behavior were also evaluated by FST.
The rats were randomly divided into the sham-treated,
dimethyl sulfoxide vehicle-treated (4% intraperitonealFigure 1 Overall experimental design. (A) The effects of TMX
on FPI-induced immobility were assessed using the FST. (E) The
effects of TMX on Erk1/2 expression in the hippocampus on Day
15 were assessed by Western blotting. (C) Immunofluorescence
staining was used to determine whether SL327 (an ERK1/2
antagonist) blocks the neuroprotective effect of TMX. ERK1/
2 Z extracellular signal-regulated kinase 1/2; FPI Z fluid
percussion injury; FST Z forced swim test; TMX Z tamoxifen.injection; Merck, K42088831; vehicle), TBI controlþ vehicle-
treated, TBI þ TMX-treated (1 mg/kg intraperitoneal injec-
tion administered on 0 hours, 24 hours, and 48 hours after
FPI; Sigma T5648, Axon, Groningen, The Netherlands, USA;
SERM), and TBI þ SL327-treated groups (30 mg/kg intraper-
itoneal injection administered 30 minutes before TBI; Axon,
Axon 1122; ERK1/2 antagonist). The dosage, administration
route, and time course of TMX injection were identical to
those used in our previous study.10 The first injection was
administered immediately after injury, followed by the
second and third injections after 24 hours and 48 hours,
respectively. The intraperitoneal route of administration
was considered convenient for the three consecutive daily
injections in our model.
All tests were performed by investigators blinded to the
study groups, which were revealed only at the end of the
analysis. The animals used for the histological or behavioral
studies were provided food and water ad libitum
throughout the study. The rats were sacrificed with an
overdose of urethane at the end of the experiments.
2.4. FST
All FST studies were conducted on Day 4, Day 8, and Day 15.
The rats were placed in clear Plexiglas cylinders [65 cm
(height)  25 cm (diameter)] filled up to 48 cm of height
with water at 25C. After 15 minutes of forced swimming,
the rats were removed from the water, dried with towels,
and placed in a warm enclosure for 30 minutes. The cylin-
ders were emptied and cleaned between two consecutive
tests. The rats were retested for 5 minutes under identical
conditions 24 hours after the forced swimming. In accor-
dance with the method described by Basso et al,16 the FST
data presented in this manuscript were collected during the
retest sessions, which were videotaped from the side of the
cylinders.
2.5. Western blot analysis
Brain tissue from the hippocampus ipsilateral to the injury
side was homogenized in the T-PER reagent at the ratio of
1:20 w/v and centrifuged (14,000 rpm) to obtain tissue
debris. The protein concentration was measured using a
bicinchoninic assay modified for microplate use. The ho-
mogenates (150 mg) were separated by sodium dodecyl
sulfate-polyacrylamide gel electrophoresis, transferred to
nitrocellulose, and incubated with a polyclonal antibody
specific for p-ERK1/p-ERK2 (StressGen Biotechnologies
Corp., cell signaling technology, Beverly, MA, USA). The
detailed information on the antibody is described herein.
Mouse Phospho-p44/42 MAPK (Erk1/2; 42 kDa, 44 kDa,
1:1000, Cell Signaling Technology, #5726), detected with
Rabbit Polyclonal Secondary Antibody to Mouse immuno-
globulin IgG H&L (HRP; 1:10,000; Abcam, ab6728, Abcam
Cambridge, FL, UK); Rabbit Polyclonal Anti-Erk1 þ Erk2
Antibody (44,42 kDa, 1:1000, Abcam, ab4819), detected
with Goat Polyclonal Secondary Antibody to Rabbit IgG H&L
(HRP; 1:10000, Abcam, ab6721); and mouse monoclonal
beta-actin (43 kDa, 1:1000; Santa Cruz Biotechnology, Santa
Cruz, CA, USA; sc-81178), detected with Rabbit Polyclonal
Secondary Antibody to Mouse IgG H&L (HRP; 1:10,000;
104 C.-C. Wang et al.Abcam, ab6728). Samples were quantified relative to the
standard, and the data are expressed as percentages of the
corresponding control group. The p-ERK1/2 levels were
measured on Day 15.2.6. Determination of p-Erk1/2, Bcl2, and BDNF
expressions in neuronal cells in the hippocampus
using an immunofluorescence assay.
On Day 15, adjacent 6-mm sections corresponding to the
coronal coordinates 4.80e6.04 mm posterior to the
bregma were incubated with primary antibodies in phos-
phate buffered saline (PBS) containing 1% normal goat
serum overnight at 4C. After being washed in PBS, the
sections were incubated with secondary antibodies for
1 hour at room temperature. The antibodies used in this
study were monoclonal mouse antineuronal-specific nu-
clear protein (NeuN, 1:800 dilution; Abcam, ab104224)
antibody, detected with Alexa-Fluor 568-conjugated
antimouse IgG antibody (1:400 dilution; Invitrogen,
A11031, Invitrogen, Eugene, Oregon, USA); rabbit anti-
BCL2 protein (1:400 dilution; Abcam; ab136285) antibody,
detected with Alexa-Fluor 488-conjugated antirabbit IgG
antibody (1:400 dilution; Invitrogen, A11034); rabbit anti-
p-ERK protein (1:200 dilution; Abcam, ab4370) antibody,
detected with Alexa-Fluor 488-conjugated antirabbit IgG
antibody (1:400 dilution; Invitrogen, A11034); and rabbit
anti-BDNF protein (1:200 dilution; Santa Cruz Biotech-
nology; sc-20981) antibody, detected with Alexa-Fluor
488-conjugated antirabbit IgG antibody (1:400 dilution;
Invitrogen; A11034).
The sections were washed in PBS, incubated with fluo-
rescein isothiocyanate-conjugated antirabbit IgG in 1%
normal goat serum/PBS/0.25% Triton-x100 for 60 minutes,
and mounted with antifade-mounting medium. The
numbers of labeled cells were calculated in two coronal
sections from each rat and are expressed as the mean
number of cells per section. To obtain negative coronal
sections, all procedures were performed using the same
protocol without the primary antibodies.2.7. Assay of neuronal apoptosis in the
hippocampus by immunofluorescence staining
On Day 15, the apoptotic cells were identified by staining
with terminal deoxynucleotidyl transferase-mediated
dUTP-biotin nick end labeling (TUNEL)20 following previ-
ously described procedures.10Figure 2 Effects of TMX (1 mg/kg, i.p.) on the TBI-induced
rats assessed by FST on Day 4, Day 8, and Day 15. * p < 0.05,
** p < 0.01 (n Z 8 in each group). FST Z forced swim test;
i.p. Z intraperitoneally; TBI Z traumatic brain injury;
TMX Z tamoxifen.2.8. Statistical analysis
All results are expressed as the mean  standard error of
the mean. A two-way analysis of variance for repeated
measurements (in the same rats) was used for the factorial
experiments, and Dunnett’s test was used for the post hoc
multiple comparisons of the means. A p value of <0.05 was
considered to indicate a significant difference.3. Results
3.1. TMX significantly reduced the duration of TBI-
induced immobility 15 days after TBI
On Day 1, the rats were subjected to lateral FPI via a
rapid injection of a small volume of saline into the closed
cranial cavity. In the FST, the TBI rats displayed despair
behavior, as indicated by an increase in the duration of
immobility 15 days after TBI (p < 0.05, n Z 6 in each
group). TBI-induced immobility was significantly lowered
when TMX was administered on Day 8 and Day 15 after
TBI. These results suggested that TMX induced
antidepressant-like behavior, particularly on Day 15 after
TBI (Figure 2).
3.2. TMX significantly enhanced the TBI-induced
reduction in total p-Erk expression in the region of
the hippocampus ipsilateral to the injury side
To determine whether ERK1/2 is involved in the antide-
pressant effects of TMX, the total expression of ERK1/2 and
p-ERK1/2 in the hippocampus was investigated by Western
blotting on Day 15 after TBI. The results reveal that the TBI-
induced reduction in the ratio of total p-ERK1/2 to total
ERK was significantly increased by TMX (p < 0.01, n Z 6 in
each group). These results support the hypothesis that
ERK1/2 is involved in the antidepressant effects induced by
TMX (Figure 3).
3.3. TMX significantly attenuated TBI-induced
neuronal apoptosis in the CA3 region of the
hippocampus ipsilateral to the injury side
The TUNEL þ Neu-N staining assay performed on Day 15
(nZ 6 in each group) revealed that the number of neuronal
Figure 3 Analysis of the effects of TMX on Erk1/2 expression
in the hippocampus on Day 15 by Western blotting. Total p-
Erk1/2 expression in the hippocampus was significantly
reduced after TBI and reversed by TMX treatment. * p < 0.05,
** p < 0.01 (nZ 6 in each group). TBIZ traumatic brain injury;
TMX Z tamoxifen.
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rats was significantly increased compared with that in the
sham group (p < 0.01). The TBI-induced increase in the
number of neuronal apoptotic cells was significantly
enhanced after TMX treatment (p < 0.05). However, the
beneficial effects of TMX were significantly reversed by
SL327 treatment (p < 0.05; Figure 4).3.4. TMX significantly increased neuronal p-ERK1/
2, Bcl2, and BDNF expression in the CA3 region of
the hippocampus ipsilateral to the injury side
On Day 15, the numbers of p-ERK1/2-positive (Figure 5A),
BCl2-positive (Figure 5B), and BDNF-positive (Figure 5C)
neurons in the hippocampi of the vehicle-treated rats were
significantly reduced compared with those in the sham
group (p < 0.05, p < 0.01, and p < 0.001, respectively;
n Z 6 in each group). The TBI-induced decrease in the
numbers of p-ERK1/2-positive, BCL2-positive, and BDNF-
positive neuronal cells were significantly improved after
TMX treatment. However, the numbers of both Neu-N and
either p-ERK1/2 or BCL2 double-positive cells were signif-
icantly reduced in the TMX þ SL327-treated group
(p < 0.05, p < 0.01, and p < 0.05, respectively; n Z 6 in
each group).3.5. SL327 significantly reversed the beneficial
effects of TMX on immobility on Day 15 after TBI
The FST revealed that the TBI-induced immobility was
significantly reduced by TMX on Day 15 after TBI
(177.6  10.8 seconds vs. 89.9  6.5 seconds, p < 0.01).
However, the beneficial effects of TMX were reversed in the
rats pretreated with SL327 (89.9  6.5 seconds vs.
162.9  2.9 seconds, p < 0.001).
4. Discussion
4.1. Novelty of the current study
TMX was administered at a dosage of 1 mg/kg for 3
consecutive days to counteract neuronal apoptosis in the
CA3 region of the hippocampus and the depression-like
behavior induced by TBI in the rats through ERK1/2-
mediated antidepressant effects. Based on our research,
this is the first study to demonstrate the antidepressant-like
effects of TMX injection in traumatic central nervous system
injury and possible involvement of ERK1/2 activation in this
TMX-induced effect. These data may serve as a foundation
for future studies on the importance of SERM therapy in TBI-
induced depression-like behavior. Our results suggest that
using TMX to stimulate ERK1/2 may be a novel strategy for
treating TBI-induced depression-like behavior in the future.
4.2. Optimal time course of TMX administration
Sato et al5 observed the maximum levels of degenerating
neurons in the cortex and hippocampus 1 day and 3 days
after TBI, respectively. Pierce et al21 also indicated that
TBI-induced functional and pathological dysfunction per-
sisted from 72 hours to 1 year after lateral FPI.17 Following
our previous study, in which we observed a significant in-
crease in TBI-induced cell apoptosis 4 days following TBI
compared with the sham group, we injected TMX for 3
consecutive days after TBI in the current study.10,22
4.3. Optimal time points for observing depression-
like behavior
The FST is a widely used and sensitive assay with good
predictive validity for depressants. The current study
demonstrated that the duration of immobility decreased on
Day 4 and increased significantly on Day 15 (p < 0.05) in the
TBI group, improving after TMX treatment on Day 15
(p< 0.001). We believe that the decrease in immobility time
on Day 4 might be associated with the struggling effects
after insult. Therefore, based on our FST measurements, we
selected Day 15 after TBI to investigate cell morphology and
biochemistry. We suggest that Day 15 after TBI could be the
optimal time for observing depression-like behavior.
4.4. Phosphorylation of ERK1/2 in the hippocampus
following TBI may be attenuated
The temporal profile of p-ERK1/2 in the hippocampus of the
rat brain from 5 minutes to 72 hours following TBI, which
Figure 4 Effects of TMX on TBI-induced neuronal apoptosis on Day 15 following TBI. The top panels depict representative Neu-N-
positive and TUNEL-positive staining for one sham rat, one TBI rat, one TBI þ TMX-treated rat, and one TBI þ TMX þ SL327-treated
rat. * p < 0.05, ** p < 0.01 (n Z 6 in each group). TBI Z traumatic brain injury; TMX Z tamoxifen; TUNEL Z terminal deoxy-
nucleotidyl transferase-mediated dUTP-biotin nick end labeling.
106 C.-C. Wang et al.presents an initial increase and a subsequent progressive
decrease, has been previously evaluated.23 Our previous
study concluded that TBI led to a significant decrease in p-
ERK1/2 in the hippocampus 72 hours after TBI.10
The Western blotting analysis revealed that the TBI-
induced decrease in the ratio of total p-ERK1/2 to total ERK
was significantly improved by TMX on Day 15 after TBI.
These findings suggest that ERK1/2 may be closely involved
in signal transduction in the rat hippocampus after TBI.
4.5. Potential involvement of ERK1/2 pathway in
the neuroprotective effects of TMX in the CA3
region of the hippocampus after TBI
Cell apoptosis is a well-known secondary insult after TBI.24
This complication has been observed in the perilesioned
areas in animal and human studies.25 Consistent withprevious studies that have reported selective invulnera-
bility to TBI induced by FPI in CA3 neurons in the hippo-
campus,4,5 the current study demonstrates that the
numbers of neurons lost and Neu-N-positive and TUNEL-
positive cells observed at the primary injury site in the
CA3 region of the hippocampus were significantly
increased on Day 15 after TBI but were reduced after TMX
treatment. These results are consistent with those
observed in studies on spinal cord injury.26 Our results
suggest that the antidepressant effects of TMX may be at
least partly due to the attenuation of apoptotic activity in
the brain tissue after TBI.
The RSKeERKeCrebeBCL2 signaling pathway was pro-
posed to promote cell survival through transcriptional
upregulation of antiapoptotic BCL2 proteins.7 Using the
brain-penetrating ERK1/2 selective inhibitor, SL327, our
study demonstrates that TMX-induced antiapoptosis in
Figure 5 (A) Effects of TMX (1 mg/kg, i.p.) on TBI-induced neuronal p-ERK1/2 staining in the hippocampus on Day 15 following
FPI. The top panels depict representative Neu-N-positive and p-ERK1/2-positive staining for one sham rat, one TBI rat, one
TBI þ TMX-treated rat, and one TBI þ TMX þ SL327-treated rat. (B) Effects of TMX on Bcl2 expression in neuronal cells in the
hippocampus (BCL2 þ Neu-N staining assay) on Day 15. The top panels depict representative Neu-N-positive and BCL2-positive
staining for one sham rat, one TBI rat, one TBI þ TMX-treated rat, and one TBI þ TMX þ SL327-treated rat. (C) Effects of TMX
on BDNF expression in neuronal cells in the hippocampus (BDNF þ Neu-N staining assay) on Day 15. The top panels depict
representative Neu-N-positive and BDNF-positive staining for one sham rat, one TBI rat, and one TBI þ TMX-treated rat. * p < 0.05,
** p < 0.01, *** p < 0.001 (n Z 6 in each group). BDNF Z brain-derived neurotrophic factor; FPI Z fluid percussion injury;
i.p. Z intraperitoneally; p-ERK1/2 Z phosphorylated ERK1/2; TBI Z traumatic brain injury; TMX Z tamoxifen.
TMX for prevention of depression after TBI 107hippocampal CA3 neurons is associated with p-ERK1/2
activation and that neuronal Bcl2 expression and the
observed beneficial effects are attenuated by pretreatment
with SL327. Increased levels of p-ERK1/2 and BCL2 in the
injured hippocampus, which decrease neuronal apoptosis,
are possible mechanisms underlying the recovery from
depression-like behavior.
BDNF is associated with neuronal survival and produces
antidepressant effects in psychiatric disorders through the
AMPAeERKeBDNF signaling pathway.8 Decreased BDNF
expression is associated with depression.27 The direct
administration of exogenous BDNF produces
antidepressant-like effects in the FST and learned help-
lessness paradigms in rats.28 The current study shows that
the TBI-induced decrease in the number of BDNF-positive
neuronal cells was significantly increased by TMX treat-
ment. The study further shows that BDNF expression was
reduced by the ERK1/2 inhibitor. Our results support the
crucial role of ERK1/2 in BDNF production,8 which is a
possible mechanism underlying its antidepressant-like ef-
fect after TBI.
The current study evaluated the effect of TMX on hip-
pocampal neurons only. Future studies should consider
clarifying whether p-ERK1/2 expression in astrocytes,microglia, and oligodendrogliocytes can induce cell
apoptosis or survival with TMX treatment after TBI.4.6. Controversial role of ERK1/2 in depression
In the current study, the activation of the ERK1/2 pathway
produced antidepressant-like effects in a TBI-induced
depression-like rat model. This result accords with that
reported by Duman et al,27 who demonstrated that using
SL327 produced a depression-like response in rats, and a
decrease in p-ERK1/2 temporally coincided with
depressive-like behavior in a rat model with a chronic
exposure to an oral corticosteroid.28 However, Fumagalli
et al29 reported that a reduction in ERK1/2 function may be
associated with the therapeutic effects of fluoxetine in a
rat model with chronic fluoxetine administration. Further-
more, Freitas et al30 demonstrated that the olfactory bul-
bectomy animal model of depression caused an increase in
p-ERK1, an effect that was abolished by fluoxetine treat-
ment. These results are inconsistent possibly because the
effects of p-ERK1/2 depend on the stimuli and cell types
involved and because the balance between the intensity
and duration of proapoptotic versus antiapoptotic signals
108 C.-C. Wang et al.transmitted by ERK1/2 determines whether a cell survives
or undergoes apoptosis.6
4.7. Controversial effects of TMX on depression
Despite the positive effects of TMX on depression-like
behavior in our study, it remains unclear whether it will
have any effect on depression under different conditions.
In a study on a female rat model, Azizi-Malekabadi et al31
suggested that the effects of TMX on depression differ
depending on the presence of ovarian hormones. In a sur-
vey of breast cancer patients, Thompson et al32 showed
that TMX increased the incidence of depressive symptoms,
whereas Lee et al33 reported no relationship between TMX
use and depression. These inconsistent results may indi-
cate that TMX has both agonistic and antagonistic effects
on estrogen receptors.34 Therefore, we considered estro-
gen receptor expression with or without TMX in our TBI
male rat model. This approach will facilitate future
investigations.
4.8. Limitations of the current study
Several limitations of the current study should be consid-
ered. First, only male rats were investigated. Future
studies should evaluate whether TMX protects female rats
from TBI-induced depression-like behavior. Second,
because of equipment limitations, FSTwas the only method
used to evaluate depression-like behavior. Third, based on
our previous study on 2,3,5-Triphenyltetrazoulium hydro-
chloride (TTC) staining,10 damage to the contralateral
injury side was not evident after FPI in our model. There-
fore, we could not determine the contralateral hippocam-
pal changes after TBI. Because depression-like behavior is a
whole-brain phenomenon, future studies should evaluate
whether damage to the hippocampus contralateral to the
injury occurs. Finally, because estrogen is associated with
depression, studies on the effects of TMX on estrogen re-
ceptor expression are warranted. Therefore, several pro-
spective studies are required.
4.9. Conclusions
An intraperitoneal injection of TMX administered at a
dosage of 1 mg/kg for 3 consecutive days, during the acute
stage attenuated TBI in rats by promoting neuronal p-Erk1/
2, Bcl2, and BDNF expression and reducing neuronal
apoptosis, resulting in antidepressant-like behavior. Our
results suggest that the ERK1/2 pathway may play a role in
mediating the behavioral effect of TMX. We also suggest
that TMX may be a promising treatment strategy for TBI-
induced depression-like behavior.Acknowledgments
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